QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

$1.85
+0.11 (+6.32%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.74
$1.86
50-Day Range
$1.67
$3.59
52-Week Range
$0.68
$3.85
Volume
231,214 shs
Average Volume
957,443 shs
Market Capitalization
$149.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.35

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
135.1% Upside
$4.35 Price Target
Short Interest
Healthy
2.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of ProQR Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

1053rd out of 1,980 stocks

Pharmaceutical Preparations Industry

517th out of 978 stocks


PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Chardan Capital Remains a Hold on ProQR (PRQR)
ProQR Therapeutics (NASDAQ:PRQR) Price Target Cut to $4.50
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
H.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)
See More Headlines

PRQR Price History

PRQR Company Calendar

Last Earnings
3/29/2023
Today
6/01/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
1,504
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.35
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.25
Forecasted Upside/Downside
+135.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-68,600,000.00
Net Margins
-1,707.31%
Pretax Margin
-1,711.09%

Debt

Sales & Book Value

Annual Sales
$4.25 million
Book Value
$0.78 per share

Miscellaneous

Free Float
74,028,000
Market Cap
$149.52 million
Optionable
Optionable
Beta
0.05

Key Executives

  • Daniel Anton de Boer
    Chief Executive Officer
  • Sheila Sponselee
    Vice President, Head-People & Operations
  • Jurriaan Dekkers
    Chief Financial Officer
  • Gerard J. Platenburg
    Chief Scientific Officer
  • Andrew Morris
    Vice President-Business Development













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings
or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued 12-month price targets for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.25 to $5.00. On average, they anticipate the company's share price to reach $4.35 in the next twelve months. This suggests a possible upside of 135.1% from the stock's current price.
View analysts price targets for PRQR
or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2023?

ProQR Therapeutics' stock was trading at $3.70 at the start of the year. Since then, PRQR stock has decreased by 50.0% and is now trading at $1.85.
View the best growth stocks for 2023 here
.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,370,000 shares, a decline of 33.5% from the April 30th total of 2,060,000 shares. Based on an average daily volume of 871,000 shares, the short-interest ratio is presently 1.6 days. Approximately 2.5% of the shares of the stock are short sold.
View ProQR Therapeutics' Short Interest
.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PRQR earnings forecast
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Wednesday, March, 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The biopharmaceutical company had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 84.97% and a negative net margin of 1,707.31%.

What ETF holds ProQR Therapeutics' stock ?

Direxion mRNA ETF holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (3.59%), Two Sigma Investments LP (0.52%), Two Sigma Advisers LP (0.46%), JPMorgan Chase & Co. (0.28%), HRT Financial LP (0.21%) and Bank of America Corp DE (0.19%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $1.85.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $149.52 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 1,504 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -